Titlebook: Biology and Treatment of Leukemia and Bone Marrow Neoplasms; Vinod Pullarkat,Guido Marcucci Book 2021 Springer Nature Switzerland AG 2021

Emg827

Current Management and New Developments in the Treatment of Myelodysplastic Syndrome,nia and propensity to transform to acute myeloid leukemia. MDS is characterized by morphologic bone marrow dysplasia and ineffective hematopoiesis resulting from a range of cytogenetic abnormalities and somatic gene mutations. Disease management varies from observation alone for low-risk disease to

拖網

Chronic Lymphocytic Leukemia (CLL): Biology and Therapy, the bone marrow and lymphoid organs. Signaling via the B-cell receptor and Bruton tyrosine kinase (BTK) as well as resistance to apoptosis mediated by Bcl-2 are hallmarks of CLL biology and have been exploited in recent years to revolutionize management. As a result of the development of novel ther

嚙齒動物

Systemic Mastocytosis: Advances in Diagnosis and Current Management,solated skin involvement is termed cutaneous mastocytosis (CM) and the term systemic mastocytosis (SM) refers to multi-organ involvement, most commonly of the bone marrow, skin, liver, and spleen. A subset of patients with SM have an associated clonal hematologic neoplasm which is most commonly myel

botany

向下

Current Management and New Developments in the Treatment of ALL, treatment approaches to newly diagnosed as well as relapsed/refractory acute lymphoblastic leukemia (ALL) have changed. This chapter summarizes the newest treatment approaches in newly diagnosed T-cell and B-cell ALL, as well as the use of novel therapies for relapsed and refractory ALL.

Neutral-Spine

conspicuous

https://doi.org/10.1007/978-3-662-59220-5decade with advances in sequencing and other molecular techniques. Besides recurrent chromosomal abnormalities detected by karyotyping or fluorescence in situ hybridization, these leukemias/lymphomas are characterized by a variety of mutations, gene rearrangements as well as copy number alterations.

corporate

mitten

Die wichtigsten Kommunikationsmodelle slow progress, the last 5?years have witnessed remarkable progress in AML therapy with the approval of multiple highly active and well-tolerated novel therapies. Notable among these are agents targeting driver mutations including FLT3, IDH1/2 as well as the Bcl-2 inhibitor venetoclax. The combinati

纖細